AZTherapies commences Ph III Alzheimer's trial; GE researching gene editing;

> AZTherapies is kicking off a Phase III study of its Alzheimer's candidate, a novel formulation of two drugs approved for other indications featuring targeted delivery specific to the disease. Release

> GE is shedding its financial business to focus on its industrial segments, as well as the life sciences. The company's Dharmacon unit has a keen interest in gene editing, known as CRISPR. "We can manipulate genes quite precisely now. The easy part is to switch proteins on and off; an even more interesting application of CRISPR-Cas9 is to change protein expression in order to create, for example, complex synthetic gene circuits," said Anja Smith, Dharmacon's director of research and development. More

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.